Stakeholder Blind Spots Boards Miss When Entering Regulated Markets

The blind spots are rarely about the regulator

Most boards approving entry into a regulated market focus their stakeholder analysis on the obvious: the lead regulator, the relevant trade body, a handful of named politicians, and the competitors most likely to complain. The work is competent. It is also incomplete in predictable ways.

What sinks regulated market entries, or quietly degrades them over the first three years, is almost never the stakeholder the board discussed at length. It is the one nobody named.

Here is where the gaps usually sit.

The supervisor below the policy team

Boards tend to map the regulator as a single entity. In practice, the policy team that wrote the rules and the supervisory team that will examine you operate with different incentives, different memories, and often different views of what good looks like. Policy may welcome your entry. Supervision may already have a thesis about firms like yours, formed from a case three years ago you have never heard of.

Good practice: identify the named supervisor likely to be assigned, understand their portfolio history, and ask what their last two enforcement matters looked like. If your advisers cannot answer this, they are not close enough.

The adjacent regulator

Financial services entry plans routinely under-weight regulators outside the prudential and conduct perimeter. The ICO, the CMA, HMRC, the Pensions Regulator, the PSR, and overseas equivalents all have standing to make your life difficult. Data protection authorities in particular have grown teeth that boards still underestimate.

The test: for each regulator outside your primary one, can you name the specific decision or guidance from the last 18 months that bears on your entry? If not, assume exposure.

The incumbents' second-order allies

Boards expect direct competitors to lobby against them. They under-prepare for the indirect coalition: the audit firms, the legal panels, the consumer groups quietly briefed by incumbents, the academics whose research the trade press will cite. These actors do not appear hostile because they are not formally aligned with anyone. Their effect is cumulative.

What good looks like: a stakeholder map that traces influence two steps out from each direct opponent, not one.

Internal stakeholders treated as executors, not actors

The Chief Risk Officer, the MLRO, the Head of Compliance, and the SMF holders carry personal regulatory liability. Their incentives are not identical to the board's. If the entry plan creates personal attestation risk they consider disproportionate, they will slow it down through entirely legitimate means: more questions, more conditions, more escalations. Boards often read this as obstruction. It is risk transfer working as designed.

Name these individuals on the stakeholder map. Ask them directly what would make them comfortable signing. If you cannot get a clear answer, you do not yet have an executable plan.

The customer cohort you are not targeting

Regulators increasingly assess market entry through the lens of consumer outcomes for groups beyond your target segment. Vulnerable customers, customers of the incumbents you will displace, and customers who fall outside your eligibility criteria all matter to the supervisor even if they do not matter to your P&L. Consumer Duty has made this explicit in the UK; similar logic is spreading.

The question to ask: who is worse off if we succeed, and who speaks for them?

The political stakeholder with no current portfolio

Shadow ministers, select committee members, and senior civil servants moving between departments shape the environment your entry matures into. Boards over-index on the current minister and under-index on who will hold the brief in 18 months. In a UK context particularly, the half-life of a relevant political relationship is shorter than most entry plans assume.

What to do before the next board meeting

Ask for the stakeholder map that supports the entry decision. Then ask three questions:

1. Who on this map could stop us, and have we spoken to them?
2. Who is not on this map but would be on a competitor's version of it?
3. Which of our own people carry personal liability for this decision, and what have they actually said?

If the answers are thin, the entry is not ready for approval. It is ready for another round of work.